initial public offerings (IPOs) trading on American exchanges

Thursday, March 6, 2014

Egalet (EGLT) began trading on the NASDAQ on 6 February 2014


Description

Egalet Corporation is a specialty pharmaceutical company developing and focuses on commercializing, abuse-deterrent oral products for the treatment of pain and in other indications. Using its technology platform, it has developed a pipeline of clinical-stage, opioid-based product candidates in tablet form that are designed to deter abuse by physical and chemical manipulation while also providing the ability to tailor the release of the active pharmaceutical ingredient (API). The Company’s lead product candidate, Egalet-001, is an abuse-deterrent, extended-release, oral morphine formulation in development for the treatment of moderate to severe pain. Its second product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation in development for the treatment of moderate to severe pain.

Address

Suite 1050, 460 East Swedesford Road
WAYNE, PA 19087
United States

Key stats and ratios

Q3 (Sep '13)2012
Net profit margin--449.46%
Operating margin--440.97%
EBITD margin--407.33%
Return on average assets-220.69%-140.37%
Return on average equity--
Employees18

No comments:

Post a Comment